Welgene Biotech Co.Ltd.
Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables… Read more
Welgene Biotech Co.Ltd. (6661) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.065x
Based on the latest financial reports, Welgene Biotech Co.Ltd. (6661) has a cash flow conversion efficiency ratio of 0.065x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$19.00 Million) by net assets (NT$293.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Welgene Biotech Co.Ltd. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Welgene Biotech Co.Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Welgene Biotech Co.Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Welgene Biotech Co.Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gibb River Diamonds Limited
F:PHO
|
-0.230x |
|
Goodyear Indonesia Tbk
JK:GDYR
|
0.057x |
|
Hochdorf Holding AG
SW:HOCN
|
-0.550x |
|
Visa Steel Limited
NSE:VISASTEEL
|
-0.005x |
|
Sadbhav Infrastructure Project Limited
NSE:SADBHIN
|
-0.797x |
|
EXCELLENCE S.A. ZY -10
F:8XY
|
N/A |
|
ASIA-PACIFIC STR.INV.LTD.
F:2HN
|
N/A |
|
Original Juice Co. Ltd.
AU:OJC
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Welgene Biotech Co.Ltd. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Welgene Biotech Co.Ltd. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$295.75 Million | NT$56.08 Million | 0.190x | +15655.68% |
| 2023-12-31 | NT$300.27 Million | NT$-366.00K | -0.001x | -100.72% |
| 2022-12-31 | NT$303.95 Million | NT$51.43 Million | 0.169x | +366.49% |
| 2021-12-31 | NT$310.06 Million | NT$11.25 Million | 0.036x | -78.05% |
| 2020-12-31 | NT$252.74 Million | NT$41.77 Million | 0.165x | -51.33% |
| 2019-12-31 | NT$250.75 Million | NT$85.14 Million | 0.340x | +71.52% |
| 2018-12-31 | NT$246.55 Million | NT$48.81 Million | 0.198x | +37.24% |
| 2017-12-31 | NT$223.63 Million | NT$32.26 Million | 0.144x | +342.94% |
| 2016-12-31 | NT$203.73 Million | NT$6.63 Million | 0.033x | +167.69% |
| 2015-12-31 | NT$199.71 Million | NT$-9.61 Million | -0.048x | -134.78% |
| 2014-12-31 | NT$114.27 Million | NT$15.80 Million | 0.138x | -- |